Tag Archives: Cancer

Avastin Gets Green Light for Use in Kidney Cancer

By George Koroneos | Published: August 5, 2009
Image by Getty Images via Daylife Score another win for Genentech and its cancer treatment Avastin (bevacizumab). On Monday, the biotech giant, now owned entirely by Roche, announced that FDA has approved the drug for kidney cancer. Avastin blocks new blood vessels from forming and supplying tumors with the nutrients they need to grow and spread to [...]
Posted in News | Also tagged , , , , , , | Leave a comment

Latest News from ASCO: Winners, Losers, and Also Rans

By Walter Armstrong | Published: June 3, 2009
Image via Wikipedia Due to pharma’s voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week’s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida. Some 4,000 studies [...]
Posted in Events | Also tagged , , , , , | 2 Comments

Coming Soon: Cancer Wars

By Patrick Clinton | Published: October 15, 2008
What if the industry develops highly effective cancer treatments and no one pays for them? BusinessWeek takes on the question in a reasonably savvy brief article this week. A sample: “At some point—and that point will come sooner rather than later—payers are not going to approve spending $100,000 for someone to live an extra six months,” [...]
Posted in Strategy | Also tagged , | Leave a comment

Lilly Puts Up $6.5 Billion for ImClone

By George Koroneos | Published: October 6, 2008
Lilly broke the news Monday morning that ImClone had accepted its offer to acquire the biotech firm for $6.5 billion or $70 per share—Lilly’s largest acquisition ever. With this purchase Lilly gains control of ImClone’s blockbuster, targeted cancer agent Erbitux, which is marketed for second- and third-line colon cancer and refractory head and neck cancer. ImClone also [...]
Posted in Biotech, Deals | Also tagged , , , , , , , | 1 Comment